Stifel analyst Paul Matteis reiterated a Hold rating and $144.00 price target on Biogen (NASDAQ: BIIB) after today's analyst/investor R&D ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE